Weekly Research Analysts’ Ratings Changes for ACADIA Pharmaceuticals (ACAD)

Several brokerages have updated their recommendations and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in the last few weeks:

• 12/29/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – ACADIA Pharmaceuticals was given a new $37.00 price target on by analysts at Stifel Nicolaus.
• 12/16/2025 – ACADIA Pharmaceuticals was given a new $37.00 price target on by analysts at Piper Sandler.
• 12/15/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a “buy” rating on the stock.
• 12/11/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a “hold” rating on the stock.
• 12/8/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $35.00 price target on the stock.
• 12/2/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Mizuho from $24.00 to $29.00. They now have a “neutral” rating on the stock.
• 12/1/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – ACADIA Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an “overweight” rating on the stock.
• 11/8/2025 – ACADIA Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/6/2025 – ACADIA Pharmaceuticals had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an “outperform” rating on the stock.
• 11/6/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director James M. Daly sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $22.37, for a total transaction of $671,100.00. Following the completion of the transaction, the director owned 4,041 shares of the company’s stock, valued at $90,397.17. This represents a 88.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mark C. Schneyer sold 10,262 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $243,106.78. Following the completion of the sale, the executive vice president owned 53,338 shares in the company, valued at $1,263,577.22. This trade represents a 16.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 44,346 shares of company stock worth $1,010,957. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.